THOR MEDICAL ASA (TRMED.OL) Stock Price, Forecast & Analysis
Europe - Euronext Oslo - OSL:TRMED - NO0010597883 - Common Stock
TRMED.OL Key Statistics, Chart & Performance
The current stock price of TRMED.OL is 5.25 NOK. In the past month the price increased by 20.97%. In the past year, price increased by 95.9%.
TRMED.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 67.75 | 44.13B | ||
| 1AE.DE | ARGENX SE | 67.67 | 44.08B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.56B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.39B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.37B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.85B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.85B | ||
| NANO.PA | NANOBIOTIX | N/A | 940.20M | ||
| 5CV.DE | CUREVAC NV | 6.24 | 815.12M | ||
| IVA.PA | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20.44 | 681.29M | ||
| FYB.DE | FORMYCON AG | N/A | 452.35M |
Related stock screener links
About TRMED.OL
Company Profile
Thor Medical ASA.engages in the producing and supplying alpha particle emitters for cancer therapy. The company is headquartered in Oslo, Oslo and currently employs 13 full-time employees. The company went IPO on 2014-07-07. The firm is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The firm is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The firm has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells
Company Info
THOR MEDICAL ASA
Karenslyst alle 9C
Oslo OSLO NO
Employees: 9
Phone: 4797414000
THOR MEDICAL ASA / TRMED.OL FAQ
Can you describe the business of THOR MEDICAL ASA?
Thor Medical ASA.engages in the producing and supplying alpha particle emitters for cancer therapy. The company is headquartered in Oslo, Oslo and currently employs 13 full-time employees. The company went IPO on 2014-07-07. The firm is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The firm is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The firm has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells
What is the stock price of THOR MEDICAL ASA today?
The current stock price of TRMED.OL is 5.25 NOK. The price decreased by -0.19% in the last trading session.
Does TRMED stock pay dividends?
TRMED.OL does not pay a dividend.
What is the ChartMill technical and fundamental rating of TRMED stock?
TRMED.OL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of TRMED stock?
THOR MEDICAL ASA (TRMED.OL) operates in the Health Care sector and the Biotechnology industry.
Is THOR MEDICAL ASA (TRMED.OL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TRMED.OL.
What is the employee count for TRMED stock?
THOR MEDICAL ASA (TRMED.OL) currently has 9 employees.
TRMED.OL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TRMED.OL. When comparing the yearly performance of all stocks, TRMED.OL is one of the better performing stocks in the market, outperforming 95.98% of all stocks.
TRMED.OL Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TRMED.OL Forecast & Estimates
9 analysts have analysed TRMED.OL and the average price target is 5.1 NOK. This implies a price decrease of -2.86% is expected in the next year compared to the current price of 5.25.